Co-Authors
This is a "connection" page, showing publications co-authored by Scott Solomon and Javed Butler.
Connection Strength
0.713
-
Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med. 2020 12 18; 18(1):403.
Score: 0.230
-
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. Eur J Heart Fail. 2018 11; 20(11):1601-1610.
Score: 0.197
-
Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 Jul 21; 76(3):280-288.
Score: 0.055
-
Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. Circulation. 2018 09 04; 138(10):1039-1053.
Score: 0.049
-
Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. Eur J Heart Fail. 2018 04; 20(4):677-686.
Score: 0.046
-
Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018 02; 20(2):281-291.
Score: 0.046
-
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail. 2017 06; 19(6):782-791.
Score: 0.045
-
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017 04 14; 38(15):1119-1127.
Score: 0.045